Indeed, recent clinical findings for patients with NSCLC treated with anti-PD-1 immunotherapy found that a higher Ki-67 expression level among PD-1+ CD8+ T-cells was a predictor for superior durable clinical benefit and survival rate35,36. Here, CD8A is linked to non-small cell lung carcinoma.